SGLT2s Best ARNI in Frail Older Adults with HFpEF
SGLT2 Inhibitors Now Recommended as First-Line Therapy for Older Adults with Heart Failure
Table of Contents
- SGLT2 Inhibitors Now Recommended as First-Line Therapy for Older Adults with Heart Failure
Understanding Heart Failure with Preserved Ejection Fraction (HFpEF)
Heart failure is a chronic condition where the heart can’t pump enough blood to meet the body’s needs. While many associate heart failure with a weakened pump (reduced ejection fraction), a significant and growing proportion of patients – especially older adults – experience heart failure with preserved ejection fraction
(HFpEF). In HFpEF, the heart muscle becomes stiff and doesn’t relax properly, hindering its ability to fill with blood. This often leads to shortness of breath,fatigue,and swelling in the legs and ankles.
HFpEF is notoriously difficult to treat. Historically, there have been limited therapies proven to improve outcomes. Conventional treatments focused on managing symptoms, such as diuretics to reduce fluid buildup, but didn’t address the underlying disease process. This has led to a significant unmet need for effective therapies specifically targeting HFpEF.
the Paradigm shift: SGLT2 Inhibitors Take Center Stage
Recent clinical trial data has dramatically altered the treatment landscape for HFpEF, particularly in frail, older adults. A growing body of evidence now supports the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors as first-line therapy. These medications,originally developed for type 2 diabetes,have demonstrated remarkable benefits in reducing hospitalizations for heart failure and improving overall survival in patients with HFpEF,*irrespective* of whether they have diabetes.
The mechanism behind this benefit isn’t fully understood, but it’s believed to extend beyond glucose control. SGLT2 inhibitors promote sodium and water excretion,reducing blood volume and strain on the heart. They also appear to have direct beneficial effects on the heart muscle itself, improving its function and reducing inflammation.
Real-World Data Confirms the Benefit
While initial excitement stemmed from clinical trials,recent real-world data reinforces the positive impact of SGLT2 inhibitors in routine clinical practice. Studies analyzing electronic health records and hospital registries consistently show that older adults with HFpEF who are prescribed SGLT2 inhibitors experience fewer heart failure-related hospitalizations and a lower risk of death compared to those who don’t receive these medications.
Who Benefits Most? Focusing on the Frail Elderly
The benefits of SGLT2 inhibitors appear particularly pronounced in frail, older adults. This population is often underrepresented in clinical trials, yet they are disproportionately affected by HFpEF and experience the greatest risk of adverse outcomes. Frailty – characterized by decreased physiological reserve and increased vulnerability to stressors – makes these patients more susceptible to the complications of heart failure.
SGLT2 inhibitors offer a relatively safe and well-tolerated treatment option for this vulnerable group. While potential side effects like urinary tract infections and dehydration need to be monitored, they are generally manageable. The ample reduction in hospitalizations and improved survival outweigh the risks for most patients.
Currently, empagliflozin and dapagliflozin are the SGLT2 inhibitors with the strongest evidence base for hfpef. Both medications have demonstrated significant benefits in clinical trials. The choice between